Association of aortic valve calcification and vitamin K antagonist treatment

Autor: Abdel Monem Kikar, Selma Hasific, Martin Busk, Jesper Hallas, and Axel Diederichsen, Oke Gerke, Flemming Hald Steffensen, Pernille Stegemejer Sønderskov, Marek Karon, Grazina Urbonaviciene, Jess Lambrechtsen, Lars Melholt Rasmussen, J. S. Lindholt, Lars Frost

Publikováno v: Sønderskov, P S, Lindholt, J S, Hallas, J, Gerke, O, Hasific, S, Lambrechtsen, J, Steffensen, F H, Busk, M, Frost, L, Urbonaviciene, G, Karon, M, Kikar, A M, Rasmussen, L M & Diederichsen, A 2020, ' Association of aortic valve calcification and vitamin K antagonist treatment ', European Heart Journal Cardiovascular Imaging, vol. 21, no. 7, pp. 718-724 . https://doi.org/10.1093/ehjci/jeaa065
Sønderskov, P S, Lindholt, J S, Hallas, J, Gerke, O, Hasific, S, Lambrechtsen, J, Steffensen, F H, Busk, M, Frost, L, Urbonaviciene, G, Karon, M, Kikar, A M, Rasmussen, L M & Diederichsen, A A 2020, ' Association of aortic valve calcification and vitamin K antagonist treatment ', European Heart Journal Cardiovascular Imaging, vol. 21, no. 7, pp. 718-724 . https://doi.org/10.1093/ehjci/jeaa065

Aims Vitamin K antagonists (VKAs) are suspected of causing aortic valve calcification (AVC). The objective of this study was to clarify whether patients undergoing VKA treatment have increased AVC scores compared to patients treated with new oral ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d97af34552d0efb3e123d8681fec483
https://findresearcher.sdu.dk:8443/ws/files/170675163/uden_6_siderEHJCI_D_20_00134_R1.pdf